Blood test detects early ovarian cancer

Key points
- Ovarian cancer is much more curable if detected early, but the disease doesn't usually produce symptoms until it is advanced and current blood tests are not very sensitive in picking it up.
- Blood levels of a protein called YKL-40 are more accurate than standard tests for other proteins - CA125 and CA15-3 - for detecting early-stage ovarian cancer, Dr.
- The team measured YKL-40 in blood samples from 46 healthy women, 61 women at high risk for ovarian cancer, 33 women with non-malignant gynecologic disorders, and 50 pre-operative patients subsequently diagnosed with early ovarian cancer.
- "YKL-40 levels distinguished normal individuals and high-risk patients from ovarian cancer patients very reliably," the authors report in the Journal of Clinical Oncology.
Ovarian cancer is much more curable if detected early, but the disease doesn't usually produce symptoms until it is advanced and current blood tests are not very sensitive in picking it up. A new test may improve the situation, researchers have shown.
Blood levels of a protein called YKL-40 are more accurate than standard tests for other proteins - CA125 and CA15-3 - for detecting early-stage ovarian cancer, Dr. Jakob Dupont of the Memorial Sloan-Kettering Cancer Center in New York and colleagues report.
The team measured YKL-40 in blood samples from 46 healthy women, 61 women at high risk for ovarian cancer, 33 women with non-malignant gynecologic disorders, and 50 pre-operative patients subsequently diagnosed with early ovarian cancer. The investigators also measured CA125 and CA15-3 levels.
"YKL-40 levels distinguished normal individuals and high-risk patients from ovarian cancer patients very reliably," the authors report in the Journal of Clinical Oncology.
They note that YKL levels were high in 72 percent of the women with early ovarian cancer, while CA125 levels were elevated in only 46 percent and CA15-3 levels in only 26 percent.
The YKL assay "has the advantage of being commercially available, easily reproducible, and inexpensive," Jakob and colleagues add.
Further studies of YKL-40 are warranted, they say, "to define the performance of the marker throughout the history of an ovarian cancer patient, including preoperative, postoperative, chemotherapy, and tumor-monitoring periods."
SOURCE: Journal of Clinical Oncology, August 15, 2004
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsNew screening strategy may catch ovarian cancer at early stages
A new screening strategy for ovarian cancer appears to be highly specific for detecting the disease before it becomes lethal. The strategy is described in a study published early online in Cancer, a peer-reviewed…
26 August 2013
NewsBlood tests could detect sexually-transmitted oral cancers
Antibodies to a high-risk type of a virus that causes mouth and throat cancers when transmitted via oral sex can be detected in blood tests many years before onset of the disease, according to a World Health…
18 June 2013
NewsScreening detects ovarian cancer using neighboring cells
Pioneering biophotonics technology developed at Northwestern University is the first screening method to detect the early presence of ovarian cancer in humans by examining cells easily brushed from the neighboring…
23 April 2013







